Graft Versus Host Disease Drug Pipeline Includes Over 50 Candidates from 45+ Companies
A new analysis report details the development landscape for Graft Versus Host Disease (GVHD), identifying over 45 companies and more than 50 drug candidates in various stages of clinical trials and research.
The pipeline for Graft Versus Host Disease (GVHD) treatments is expanding, with over 45 companies actively developing more than 50 drug candidates. DelveInsight's "Graft versus host disease Pipeline Insight 2026" report provides a comprehensive overview of these efforts, detailing clinical strategies and emerging therapeutics.
The report analyzes pipeline drugs, covering both clinical and non-clinical stages, and assesses therapeutic approaches by product type, stage, route of administration, and molecule type. It also highlights inactive pipeline products in the field.
Recent developments include expedited regulatory approval from Brazil's ANVISA for axatilimab, developed by Incyte Corporation and Syndax Pharmaceuticals Inc., for chronic GVHD in specific patient populations. However, Syndax Pharmaceuticals also announced that axatilimab did not meet its primary endpoint in a Phase II trial for idiopathic pulmonary fibrosis, though this result is not expected to affect ongoing chronic GVHD trials.
Additionally, Incyte Corporation's ruxolitinib 1.5% cream (Opzelura) showed positive results for cutaneous chronic GVHD in a study published in The Lancet Haematology, reducing affected skin area compared to placebo. Several companies, including Abbisko Therapeutics, Equillium, and Theriva Biologics, are advancing various drug candidates.
Graft versus host disease is a serious complication following allogeneic stem cell or bone marrow transplants, where donor immune cells attack the recipient's body. It can occur in acute or chronic forms, impacting various organs and systems.